IOVA Insider Trading Activity and SEC Form 4 Filings
IOVA insider trading summary
No open-market insider purchases or sales of Iovance Biotherapeutics, Inc. (IOVA) have been reported on SEC Form 4 in the past 12 months.
Latest IOVA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 5, 2025 | Daniel Gordon Kirby | Chief Commercial Officer | Buy | $55K (30,000 @ $1.84) |
| May 23, 2025 | Raj K. Puri | Chief Regulatory Officer | Buy | $10K (5,600 @ $1.74) |
| May 14, 2025 | Frederick G Vogt | Interim CEO & General Counsel | Buy | $42K (25,000 @ $1.69) |
| Nov 12, 2024 | Ryan D Maynard | Director | Sell | $503K (50,000 @ $10.06) |
| Feb 20, 2024 | Iain D. Dukes | Director | Buy | $293K (32,000 @ $9.15) |
| Feb 20, 2024 | Merrill A McPeak | Director | Buy | $2.3M (250,000 @ $9.15) |
| Feb 20, 2024 | Wayne P. Rothbaum | Director | Buy | $45.8M (5,000,000 @ $9.15) |
| Sep 18, 2023 | Merrill A McPeak | Director | Buy | $56K (10,000 @ $5.56) |
| Sep 15, 2023 | Wayne P. Rothbaum | Director | Buy | $26.5M (5,000,000 @ $5.30) |
| Dec 21, 2022 | Merrill A McPeak | Director | Buy | $62K (10,000 @ $6.15) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.